BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ: BMRN · IEX Real-Time Price · USD
89.49
+0.86 (0.97%)
At close: Apr 22, 2024, 4:00 PM
89.00
-0.49 (-0.55%)
After-hours: Apr 22, 2024, 7:40 PM EDT
0.97%
Market Cap 16.98B
Revenue (ttm) 2.42B
Net Income (ttm) 167.65M
Shares Out 189.78M
EPS (ttm) 0.87
PE Ratio 102.86
Forward PE 53.63
Dividend n/a
Ex-Dividend Date n/a
Volume 1,233,796
Open 89.46
Previous Close 88.63
Day's Range 88.89 - 89.81
52-Week Range 76.02 - 99.56
Beta 0.32
Analysts Buy
Price Target 108.28 (+21.0%)
Earnings Date Apr 24, 2024

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 23, 1999
Employees 3,401
Stock Exchange NASDAQ
Ticker Symbol BMRN
Full Company Profile

Financial Performance

In 2023, BMRN's revenue was $2.42 billion, an increase of 15.42% compared to the previous year's $2.10 billion. Earnings were $167.65 million, an increase of 18.43%.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is $108.28, which is an increase of 21.00% from the latest price.

Price Target
$108.28
(21.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET

SAN RAFAEL, Calif. , April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a con...

12 days ago - PRNewsWire

New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Investigator-Sponsored Phase 2 Study Demonstrated Positive Results for VOXZOGO in Children with Hypochondroplasia New Analyses Highlight VOXZOGO 7-year Data and Improvement on Quality of Life in Child...

5 weeks ago - PRNewsWire

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif. , March 7, 2024 /PRNewswire/ -- BioMarin P...

6 weeks ago - PRNewsWire

BioMarin Scheduled to Participate in March Investor Conferences

-       Cowen 44th Annual Healthcare Conference on March 5 -       Leerink Partners Global Biopharma Conference on March 11 -       Jefferies Biotech on the Bay Summit on March 12 -       Barclays 26t...

7 weeks ago - PRNewsWire

BioMarin Pharma gets DOJ subpoena on certain drug testing programs

BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, it said in a filing on...

2 months ago - Reuters

BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024

Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earnings per Share of $2.08 (+36% Y/Y) VOXZ...

2 months ago - PRNewsWire

BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET

SAN RAFAEL, Calif. , Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe...

2 months ago - PRNewsWire

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress

New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostatic Benefit for Adults with Severe Hemophilia A SAN RAFAEL, Calif. , Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nas...

2 months ago - PRNewsWire

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA

SAN RAFAEL, Calif. , Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at t...

3 months ago - PRNewsWire

Biotech stocks set for a rebound in 2024, analysts say

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

4 months ago - Market Watch

BioMarin settles with Elliott, adds 3 independent directors

NEW YORK, Dec 20 (Reuters) - BioMarin (BMRN.O) reached a settlement with activist investor Elliott Investment Management where the biotechnology company will add three independent directors to its boa...

4 months ago - Reuters

BioMarin Announces Governance Enhancements and Value Creation Initiatives

Board Approves Appointment of Three New Independent Directors Company Establishes Strategic and Operating Review Committee of the Board BioMarin Enters into Cooperation and Information Sharing Agreeme...

4 months ago - PRNewsWire

BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany

ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in Germany SAN RAFAEL, Calif. , Nov. 28, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global bio...

5 months ago - PRNewsWire

Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources

Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical and has been in discussions with the biotechnology company for months about its future, according to two pe...

5 months ago - Reuters

BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year

• Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO® and ROCTAVIAN® Net Product Revenue Guidance Adjusted for Full-year 2023 • VOXZOGO Now Approved for Children...

6 months ago - PRNewsWire

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer

Mr. Hardy Brings More than 30 Years of Industry Experience, Most Recently as CEO of Genentech Mr. Bienaimé Served as CEO for 18 Years and as Chairman since 2015, Steering BioMarin to Profitability wit...

6 months ago - PRNewsWire

U.S. FDA approves expanded use of BioMarin's dwarfism therapy

The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children under the age of 5 with the most common form of shor...

6 months ago - Reuters

U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

Expanded Indication in the U.S. Now Includes Children of all ages with Achondroplasia SAN RAFAEL, Calif. , Oct. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechno...

6 months ago - PRNewsWire

BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET

SAN RAFAEL, Calif. , Oct. 17, 2023  /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host ...

6 months ago - PRNewsWire

BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting

Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4 SAN RAFAEL, Calif. , Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotech...

7 months ago - PRNewsWire

Investors should stick to the ‘late cycle playbook' and buy these sectors, says Morgan Stanley's Mike Wilson

Investors stumped as to where the U.S. economy is situated in the current business cycle, should be focusing on late-cycle stock sectors, which includes one that has been heating up of late.

Other symbols: ACNAZOBSXAAPL
7 months ago - Market Watch

BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia

European Commission Approval Decision Expected Q4 2023 Opinion Based on Positive Results from Global Phase 2 and Ongoing Extension Study  U.S. Food and Drug Administration PDUFA Target Action Date for...

7 months ago - PRNewsWire

BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York

Live Audio Webcast to Begin at 8:00 a.m. Eastern Time SAN RAFAEL, Calif.

8 months ago - PRNewsWire

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

BioMarin Leadership and External Medical Experts to Discuss 7 Product Candidates in Clinical Development as well as ROCTAVIAN and VOXZOGO New Indication Opportunities R&D Day to be Webcast Beginning a...

8 months ago - PRNewsWire

BioMarin to Participate in Three Upcoming Investor Conferences

Citi's 18th Annual BioPharma Conference on September 6 at 3:30pm ET Morgan Stanley 21st Annual Global Healthcare Conference on September 11 at 10:00am ET Baird's 2023 Global Healthcare Conference on S...

8 months ago - PRNewsWire